Japan has granted the first approval worldwide for a Janus kinase (JAK) inhibitor in topical form, issuing a nod for Japan Tobacco Inc.’s Corectim (delgocitinib; JTE-052) in the second-line treatment of adult atopic dermatitis.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?